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Markov model with 3 stages: disease progression, disease free progression and
death in a time horizon of 3 years. Costs were based on direct medical costs of the
institution, drug administration costs and cost for the management of adverse
events and they are expressed in US dollars. RESULTS: The average treatment cost
for the alternatives were: $ 16,133.78 for XELOX, $ 25,690.58 for FOLFOX-4, $
27,686.35 for FOLFOX-6 and $ 21,904.12 for FOLFIRI. XELOX is the least costly alter-
native. The difference in costs ismainly due to the difference inmanagement costs
and the presence of grade 3-4 adverse events, mainly neutropenia. Based on clin-
ical trials, FOLFOX-6 presented neutropenia (47%), FOLFOX-4 (44%) and FOLFIRI
(26%), while the most severe adverse event was diarrhea with XELOX (12%). In the
disease management, FOLFOX-6, FOLOFX-4 and FOLFIRI require two hospitaliza-
tions per cycle for the application of the drug. Instead, XELOX requires only one
chemotherapy session. Since Capecitabine is orally administered, not only mini-
mizes the costs of administration, also has a better safety profile with less adverse
events. CONCLUSIONS: The use of Capecitabine combined with Oxaliplatin
scheme as first-line treatment of metastatic colorectal cancer, is the alternative
that minimizes costs to the health institutions, as well as improve quality of life
resulting from Capecitabine’s oral administration.
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OBJECTIVES: To identify which of the different chemotherapy alternatives minimizes
costs for the treatment of advanced and/or metastatic Gastric Cancer (GC) in Mexico.
METHODS: A cost minimization was performed considering the alternatives: EOX
(epirubicinoxaliplatincapecitabine), EOF (epirubicinoxaliplatinfluorouracil),
ECX (epirubicincisplatincapecitabine) and ECF (epirubicincisplatin fluorou-
racil) for the treatment of advanced and/ormetastatic gastric cancer (advGA) using
aMarkovmodel with 3 stages: progression, disease free progression and death. For
a time horizon of 3 years, it was taken into account direct medical costs for the
diseasemanagement, drug and its application cost, and costs incurred in theman-
agement of the associated adverse events. Costs are expressed in USD dollars.
RESULTS: ECXwas the alternativewith less costs ($6,293), followed by EOX ($7,692).
The chemotherapy combinations based on capecitabine proved to be the least
expensive. The alternative EOF had a cost of $10,904, while ECF was $9,873. The
factor that increased costs of EOF and ECF was the drug administration costs, as
they require to be administered as daily intravenous infusions in comparison of the
oral administration of capecitabine. Therefore, the administration costs of ECX and
EOX represent only 4.76% of the administration costs of ECF and EOF. The results of
the univariate sensitivity analysis confirmed savings with capecitabine versus ECF
from$5,721 to $6,209 and versus EOF from$5,691 to $6,178 in the totalmanagement
costs. The probabilistic analysis results also confirmed that in the ECF scheme
versus ECX, the combination with capecitabine is a cost-saving alternative. ECX
and EOX are alternatives that minimize costs at 100% of cases compared to ECF
and EOX respectively. CONCLUSIONS: The oral administration of capecitabine is
the factor that minimizes the cost of the alternatives in the chemotherapy combi-
nation schemes, also, the safety profile of capecitabine helps incurring in less costs
associated to the management of side adverse events.
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OBJECTIVES: CML is a clonal myeloproliferative neoplastic disorder characterized
by a reciprocal translocation between chromosomes 9 and 22, t(9;22)(q34;q11) lead-
ing to the formation of the BCR-ABL fusion gene.With the introduction of imatinib,
a BCR-ABL tyrosine kinase inhibitor (TKI), survival has improvedwith durable long-
term responses. Nilotinib is a more recently approved second generation TKI indi-
cated for treatment of CML as first- and second-line therapy. Shorter-term clinical
trials (24months) have shown that nilotinib produces a faster cytogenetic response
compared to imatinib, but long-term survival outcomes have not yet been reported
in clinical trials. The objective of this analysis is to explore the cost-effectiveness of
nilotinib compared to imatinib for the treatment of newly diagnosed CML in
chronic phase. METHODS: Using a healthcare payer perspective, a 72-month
Markov state transition model was developed in Microsoft Excel 2007. Major cyto-
genetic response, progression, and survival rates were obtained from a 24-month
head-to-head clinical trial and a 72-month single arm trial evaluating long-term
responses with imatinib. Nilotinib as a second-line therapy was allowed for pa-
tients who progressed while on imatinib. Drug costs were obtained from the Red
Book. Hospital and outpatient costs were obtained from reimbursement rates from
the Centers for Medicare and Medicaid Services. Sensitivity analyses were con-
ducted to test various assumptions. RESULTS: The base case analysis resulted in
0.1 life years gained for nilotinib compared to imatinib. Resultant quality-adjusted
life years (QALYs) for nilotinib and imatinib were estimated to be 4.39 and 4.23,
respectively. The additional cost for treating with nilotinib was $213,895, resulting
in an incremental cost effectiveness ratio (ICER) of greater than 1million dollars per
QALY saved. CONCLUSIONS: Based upon this analysis, the small additional sur-
vival benefits associated with nilotinib do not translate into a favorable ICER for
first-line treatment of CML in chronic phase.
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BACKGROUND: Approximately 60% of breast cancer cases are hormone sensitive.
Tamoxifen is the most widely used treatment of hormone-dependent breast can-
cer. The pharmacological activity of tamoxifen is dependent on its conversion by
the hepatic drug-metabolizing enzyme CYP2D6. Patients with reduced CYP2D6
activity may derive inferior therapeutic benefit from tamoxifen, and may alterna-
tively be treated with newer aromatase inhibitors (AIs) sequentially or as mono-
therapy. However, the higher costs of AIs provide incentive for identifying patients
who will benefit from tamoxifen prior to treatment. OBJECTIVES: To evaluate the
cost-effectiveness of adjuvant mono and sequential hormone therapies, and
CYP2D6 testing in combination with tamoxifen mono and sequential (with AIs)
therapies for ER hormone sensitive women with early breast cancer in Canada.
METHODS:Weperformed a cost-effectiveness analysis using aMarkovmodel from
a societal perspectivewith a lifetime horizon. An embedded decision treewas used
to identify best treatment strategy according to CYP2D6 gene polymorphisms. Our
comparator is optimal treatment strategy without genetic testing. Patient popula-
tion is 65-year-old ER hormone sensitive women with early breast cancer. Ex-
pected value of perfect information was performed to identify future research
directions. Probabilistic sensitivity analysis was used to incorporate parameter
uncertainties. Outcomes were quality-adjusted life years (QALYs) and costs.
RESULTS: Our preliminary analysis suggested that the genetic testing and treat-
ment combination strategy were marginally more effective (0.005 QALY gained)
and cost CAD $102 more when compared to no testing (letrozole-tamoxifen se-
quential therapy). The incremental cost-effectiveness ratio (ICER) for the base case
was $21,732 per QALY. The results were sensitive to assumptions related to disease
progression,mortality rate and the drug cost. CONCLUSIONS: Themarginal gain in
effectiveness and extra cost may not warrant a recommendation for routine
CYP2D6 genetic testing in combination with tamoxifen monotherapy for ER
women with early breast cancer in the current setting.
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OBJECTIVES: The cost-effectiveness analysis compares plerixafor GCSF for stem
cell mobilization in Canada compared to using GSCF alone or GCSF  chemother-
apy in patients with multiple myelemo (MM) or non-Hodgkins’s lymphoma (NHL)
whose cellsmobilize poorly. NHL andMMare severe forms of hematological cancer
where autologous hematopoietic stem cell (HSC) transplantation is a standard of
care in Canada. In order to proceed to transplantation, a sufficient number of stem
cells need to be harvested during apheresis. Patients who collect 2 million HSCs
proceed to transplant. Those whose peripheral blood CD34 cell count on the day
before apheresis is below the range of 10 to 20 cells/uL is generally considered a
poor mobilizer. METHODS: The model uses a cohort semi-Markov process that
embeds two decision trees for autologous transplantation and continuation of
care. The Markov structure based on annual cycles consists of three health states -
Remission, Well and Death. The mobilization decision tree includes the pre-
apheresis, apheresis and transplant pathways. The continuation of care includes a
series of therapies currently used in Canadian clinical practice following failed
mobilization or relapse. Patients enter remission after successful transplantation
and continuation of care after unsuccessful transplantation. RESULTS: The results
showed that incremental cost-effectiveness ratio (ICER) for plerixafor  GCSF
verses GCSF alone was $19,191 for NHL and $60,835 for MM. When compared to
GCSF  chemo, the ICER was $14,330 for NHL and $31,622 for MM patients. Deter-
ministic sensitivity analysis was conducted to assess extreme values and model
uncertainty. Probabilistic sensitivity analysis was conducted to generate cost-ef-
fectiveness acceptability curves. Major data limitations include probability of suc-
cessful mobilization and number of apheresis days for GCSFchemo comparator.
CONCLUSIONS: The results show that plerixafor  GCSF, when used in the poor
mobilizer setting, is a cost-effective strategy for both NHL and MM patients in
Canada.
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OBJECTIVES: To identify the drug that offers the best pharmacoeconomic result for
the treatment of advanced or metastatic NSCLC previously treated with a chemo-
therapy regimen in public health institutions in Mexico. METHODS: It was devel-
oped a cost-utility analysis using a Markov model with monthly cycles in a time
horizon of 2 years. Themain output indicators were: Years of Quality Adjusted Life
(QALY’s) and total treatment cost per patient. The alternatives in the study were:
Erlotinib, Docetaxel and Pemetrexed. Costs are expressed in US dollars. RESULTS:
The average cost per patient for Erlotinib was $9,862, and $21,583 to $24,049 for
Docetaxel and Pemetrexed. Erlotinib provided 0.33 QALY’s, while Docetaxel pro-
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vided 0.30 and Docetaxel 0.31. Therefore, Erlotinib therapy is positioned as a dom-
inant (more effective and less costly) compared to Docetaxel and Pemetrexed.
These results were consistent in the sensitivity analysis, giving strength to them.
Therefore, Erlotinib could represent annual savings of $5860 compared to Do-
cetaxel and $7090 with Pemetrexed per patient. Additionally, Erlotinib contributes
to costs reduction in patients with NSCLC, because it is a chemotherpay adminis-
tered orally, instead os a intravenous infusion, andwith a better safety profilewithno
hematologic toxicity in comparison with standard chemotherapy. CONCLUSIONS:
The cost-utility analysis of the use of Erlotinib vs. Docetaxel or Pemetrexed in the
treatment of previously treated metastatic or advanced NSCLC showed that Erlo-
tinib is a cost-effective therapy because it consumes fewer resources to obtain
clinical success. Under the perspective of the Mexican public health system Erlo-
tinib is dominant alternative in second-line treatment for patients with advanced
or metastatic NSCLC.
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OBJECTIVES: Cancer is the second leading cause of death in the Slovak Republic
with 23 000 new cases diagnosed every year and highest incidence in age group
over 60. Antineoplastic agents prevent or inhibit the maturation and proliferation
of neoplasms. Themain objective of this studywas to evaluate the consumption of
antineoplastic agents in Slovak Republic within the period of 2008-2011.
METHODS: Analysed data were abstracted from the Slovak Institute of Drug Con-
trol and provided by wholesalers due to their legal obligation towards the SIDC.
Processed informations include the number of medicine packages and financial
expenditures. RESULTS: There was a gradual rise in antineoplastic agents utilisa-
tion in terms of financial expenditures from 98 605 418 € in 2009 to 105 786 256 € in
2011. Third quartal of 2010 was hitting a peak with 27 261 629 € respectively while
the first quartal plummeted to 23 307 249 €, which presents the lowest performance
within followed period. Number of packages rose sequentially from 513 193 in 2008
to 593 067 in 2011. Average price per package was fluctuating from 168 € in 2010 to
192 € in 2008. Highest financial declinewas observed in group of plant alkaloids and
other natural products ( from 12 977 717 € in 2008 to 6 840 618 € in 2011). Most
significant expeditures increase from the group of antineoplastic agents reached
capecitabinewith 3 491 954 € in 2008 and 4 560 623 € in 2011. Its number of packages
almost doubled from 8 725 in 2008 to 14 145 in 2011. CONCLUSIONS: The slight rise
in consumption of antineoplastic agents is caused by higher incidence and preva-
lence and better diagnose of cancer disease in Slovak population. Higher use of
capecitabine can be interpretted in pursuance of breast and colorectal cancer oc-
curence.
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OBJECTIVES: Innovative pharmaceutical treatments contribute significant value
for improving and extending the lives of cancer patients. Many innovative oncol-
ogy products become standard of care and continue to produce significant value
well beyond the period of innovator exclusivity. Current tools used to guide 3rd
party funding decisions are made at the beginning of product lifecycles and fail to
account for the long-term stream of value, particularly from acquisition cost re-
duction after innovator exclusivity. The objective of this study was to propose a
framework to highlight this important aspect for determining the value of new
drug innovation using two case studies. METHODS: The drugs selected for the
cases studies were paclitaxel and azacitidine. Pharmacoeconomic studies evaluat-
ing these agents were identified. Applying off-patent prices after exclusivity, a
lifecycle ICER was determined by annually amortizing the ICER value over the
potential useful life of a product. Results are in Canadian dollars. RESULTS: Pacli-
taxel remains a standard of care in advanced ovarian and breast cancer even after
innovator loss of exclusivity in 2004. Using the current off-patent price, the lifecycle
ICER for paclitaxel is estimated to be approximately $26,000 per QALY. Azacitidine
has become the standard of care for higher-risk MDS in Canada. It is anticipated
that azacitidine will remain part of standard care beyond innovator exclusivity.
Assuming a 25% reduction in acquisition cost and a further 10 year useful life, the
lifecycle ICER for azacitidine is estimated to be approximately $36,000 per QALY.
CONCLUSIONS: Many innovative oncology medicines provide significant societal
value well past the period of innovator exclusivity. Current approaches for assess-
ing economic value fail to recognize this unique aspect and may be undervaluing
new oncology medicines. Therefore, approaches should evolve to better account
for the societal value a product produces over its useful life span.
CANCER – Patient-Reported Outcomes & Patient Preference Studies
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OBJECTIVES: Identify explanatory variables of hormone therapy (HT) adherence
and persistence (A&P) in women with breast cancer (BC), and evaluating the effect
of such variables in BC survival rates. METHODS: Retrospective longitudinal data
from a cohort of 5861 women with BC, submitted to HT, was put together through
linkage of the Brazilian National Cancer Institute datasets, including the control of
medicines delivered at its Pharmacy. A logistic regression model was applied to
study adherence. Cox proportional hazard models were used to estimate persis-
tence and BC survival. RESULTS: The proportion of treatment adherent was 75.3%.
At the end of the first and the fifth year of treatment, respectively, overall persis-
tence to treatment was 79% and 31%, and survival was 94% and 71%. Similarly,
better A&P to treatment, as well as BC survival, were associated with higher edu-
cation, having a partner, lower cancer stages, being submitted to surgery, having
less inpatient care, making outpatient visits to a Mastologist and a Clinical Oncol-
ogist, and the need of less exams. Older women were more likely to adhere and to
persist to treatment, but those aged 70 years old or more presented higher hazard
of death. Alcoholism and tobacco use was associated with lower A&P. Longer time
between diagnosis and the beginning of HT and cancer family historywere, respec-
tively, a risk and a protective factor to treatment persistence and survival. Psycho-
therapy was protective for adherence and survival. Finally, treatment adherence
was positively associated with BC survival, being combined tamoxifen and aroma-
tase inhibitor explicative of lower adherence, while only aromatase inhibitor use
was associated with higher hazard of death. CONCLUSIONS: In this cohort, of
the patients did not adhere, only 31% completed the 5-year hormone treatment,
and 71% were alive after five years. Socio-demographic, behavioral, clinical and
health care aspects explained partially variations in these dependent variables.
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OBJECTIVES: Since the launch of Imatinib, the survival of chronic myeloid leuke-
mia (CML) has significantly improved, but also caused enormous increase in long-
termcosts of CML care. Neither health-related utility of CMLpatients nor long-term
cost-effectiveness of imatinib, however, has been investigated in Taiwan. This
feasibility study aims to explore the applicableness of time-trade-off (TTO) tomea-
sure utility of CML patients treated with imatinib.METHODS: This cross-sectional
study was conducted at a medical center in southern Taiwan from June 2011 to
January 2012. Outpatients with defined diagnosis of CML and receiving imatinib
were invited to participate. After TTO measurement, semi-structure interviews
were conducted to explore participates’ perceptions. The interviews were audio-
taped, transcribed verbatim and analyzed by constant comparison untill
saturation. RESULTS: Of all, 22 (mean age: 52.415.83 years, male: 63.6%) of the 24
participants completed the study. The average utility was 0.7740.219. Most par-
ticipants accepted current health status and life expectancy, and considered cur-
rent health status is not different from ideal situation. Mid-age participants traded
off life span with parenting duty, while the elderly considered companion time
with their partners. For those who chose shorter life span with better health, the
main concern was financial burden to family because the disease-related fatigue
constrained activity and work ability. In addition, regular medical treatment was
also considered by those who desired better career paths, long-term traveling and
those consisting ofmulti-comorbidity. Moreover, uncertainty about future, limited
social support and financial difficulty were also the reasons for trading off.
CONCLUSIONS: TTO is applicable to measure utility for CML patients. Participants
receiving imatinib generally presented satisfactory health status and trading re-
maining years of lifewith other concerns. To validate this tool, further studies need
to explore utilities of patients with disease symptoms or drug-related side effects,
and compare the results with disease-specific measures.
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OBJECTIVES: The limitations of generic preference-based measures in disease ar-
eas such as oncology are widely recognised. Condition-specific measures offer
more relevant assessments of health and can be used to derive utilities. The aim of
this study was to use data collected with the European Organization for Research
and Treatment of Cancer (EORTC) Quality of Life Questionnaire for Cancer (QLQ-
C30) in a myelofibrosis clinical trial to derive utilities. METHODS: QLQ-C30 data
were collected over 48 weeks in an open-label trial of ruxolitinib (n146) versus
best-available therapy (BAT) (n73). Two algorithms were used to map QLQ-C30
scores to utilities: the first mapped to EQ-5D utilities, the second to condition-
specific preference weights using a QLQ-C30 item subset (EORTC-8D). Changes
from baseline (CFB) in utilities were calculated by treatment at week 48. Mean
utilities by presence of constitutional symptoms (CS) (weight loss, fever or night
sweats) and response (35% reduction in spleen volume from baseline) were also
derived. RESULTS:Mean (SE) utility CFB from the EQ-5D algorithmwas 0.082 (0.025)
for ruxolitinib and 0.012 (0.040) for BAT. From the EORTC-8D algorithm, mean (SE)
CFB was 0.038 (0.013) for ruxolitinib and 0.013 (0.021) for BAT. Patients without CS
had highermean (SE) utilities than patientswith CS using both algorithms—EQ-5D,
0.730 (0.017) without and 0.539 (0.031) with CS; EORTC-8D, 0.818 (0.009) without and
0.719 (0.016) with CS. Similarly, patients defined as responders had higher mean
(SE) utilities than nonresponders using both algorithms—EQ-5D, 0.754 (0.029) for
responders and 0.670 (0.024) for nonresponders; EORTC-8D, 0.843 (0.015) for re-
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